STO · SOBI.ST
Swedish Orphan Biovitrum AB
SEK 488.00+SEK 9.80 (+2.05%)
Swedish Orphan Biovitrum AB’s quoted price sits in the upper half of its reported 52-week range, 0.81% below the high.
Loading market information…
STO · EKTA-B.ST · SEK
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 04:29 PM UTC. Cached market data; not a live quote.
One-year closing-price history · SEK. Historical prices are not a forecast.
Elekta AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 12.29% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Elekta AB (publ)’s forward annual dividend is SEK 2.40 per share, paid semi-annual. The forward yield is 4.1% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Elekta AB (publ)’s next earnings report is currently expected on Nov 25, 2026, with estimated earnings per share of SEK 0.82. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Elekta AB (publ)’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Elekta AB (publ) operates as a global medical technology company, delivering advanced clinical solutions for managing cancer and various brain disorders. Its extensive oncology offerings include sophisticated radiation therapy systems such as Versa HD, tailored for brain metastases; the groundbreaking Elekta Unity, leveraging MR-Linac technology; linear accelerators like Elekta Harmony; and Elekta Infinity, designed to address diverse radiotherapy needs. The company also provides Elekta Synergy, a digital accelerator for advanced image-guided radiation therapy. Beyond primary treatment devices, Elekta supplies comprehensive treatment management solutions, automated and integrated quality assurance tools, and hardware/software for motion management. Specialized oncology platforms feature MOSAIQ Plaza for multidisciplinary cancer care, the managed hosting service Elekta Axis Cloud, and Elekta Studio for image-guided brachytherapy. Complementary hardware includes the ImagingRing mobile CT scanner. For brachytherapy, they offer smart tools like Oncentra Brachy to streamline repetitive tasks, alongside applicators such as Venezia and Geneva for cervical cancer treatment, and the Elekta Flexitron afterloader for precise workflow execution. In the field of neurosurgery and radiosurgery, Elekta provides the Leksell Gamma Knife series, including Icon for personalized radiation treatment, Perfexion as a vital tool for neurosurgeons, and Lightning for accelerated radiosurgery. Their neurosurgery product line further encompasses the Leksell Vantage Stereotactic System for intracranial procedures and the Leksell Stereotactic System for minimally invasive interventions. Elekta AB (publ) was founded in 1972 and is headquartered in Stockholm, Sweden.
Latest available per-share figures in SEK. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:43 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q4 2025 | May 28, 2025 | SEK 1.11-16.54% vs estimate | SEK 5.16B+0.75% vs estimate |
|---|
| Q3 2025 | Feb 21, 2025 | SEK 0.94-10.1% vs estimate | SEK 4.70B-1.82% vs estimate |
|---|
| Q2 2025 | Nov 27, 2024 | SEK 0.64-17.35% vs estimate | SEK 4.34B-2.66% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
SEK 488.00+SEK 9.80 (+2.05%)
Swedish Orphan Biovitrum AB’s quoted price sits in the upper half of its reported 52-week range, 0.81% below the high.
SEK 273.40+SEK 1.50 (+0.55%)
Getinge AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 0.18% below the high.
SEK 341.60+SEK 2.80 (+0.83%)
Sectra AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 0.29% below the high.
SEK 279.50+SEK 2.00 (+0.72%)
Medicover AB (publ)’s quoted price sits in the upper half of its reported 52-week range, 0.89% below the high.
SEK 670.00SEK 0.00 (0.0%)
Camurus AB’s quoted price sits in the upper half of its reported 52-week range, 5.63% below the high.
SEK 319.40-SEK 0.80 (-0.25%)
BioArctic AB’s quoted price sits in the upper half of its reported 52-week range, 12.35% below the high.
SEK 202.40+SEK 4.40 (+2.22%)
RaySearch Laboratories AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 23.48% below the high.
SEK 23.20+SEK 1.70 (+7.91%)
C-Rad AB (publ)’s quoted price sits in the lower half of its reported 52-week range, 41.12% below the high.
